Co-Diagnostics, Inc.CODX
Price (close)
$1.09
Market cap
$5.3M
P/E
—
Revenue (TTM)
$721,387
Net income
-$47.1M
Dividend yield
—
1-year total return
-90.3%
Net margin
-6523.0%
Revenue growth
-28.1%
Debt / equity
—
What Co-Diagnostics, Inc. does.
tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection
of infectious diseases. Our diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by
automating or simplifying historically complex procedures in both the development and administration of tests. CODX’s technical
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $74.6M | $97.9M | $34.2M | $6.8M | $3.9M | $622,489 |
| Net income | $42.5M | $36.7M | -$14.2M | -$35.3M | -$37.6M | -$46.9M |
| Free cash flow | $27.4M | $40.4M | $5.1M | -$23.4M | -$29.9M | -$29.8M |
More on CODX.
- Co-Diagnostics, Inc. summary
- Co-Diagnostics, Inc. financial statements
- Co-Diagnostics, Inc. key metrics
- Co-Diagnostics, Inc. health scores and style box
- Co-Diagnostics, Inc. earnings
- Co-Diagnostics, Inc. dividends
- Co-Diagnostics, Inc. valuation
- Co-Diagnostics, Inc. ownership and insiders
- Co-Diagnostics, Inc. peers
Figures from Co-Diagnostics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.